Zoetis Inc. (NYSE:ZTS) Shares Bought by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich raised its holdings in Zoetis Inc. (NYSE:ZTS) by 12.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 565,699 shares of the company’s stock after purchasing an additional 63,950 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in Zoetis were worth $111,652,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ZTS. International Assets Investment Management LLC boosted its stake in shares of Zoetis by 25.1% in the third quarter. International Assets Investment Management LLC now owns 1,726 shares of the company’s stock worth $302,000 after acquiring an additional 346 shares during the last quarter. Capital Investment Advisors LLC boosted its stake in shares of Zoetis by 38.1% in the third quarter. Capital Investment Advisors LLC now owns 2,263 shares of the company’s stock worth $394,000 after acquiring an additional 624 shares during the last quarter. Flagship Harbor Advisors LLC acquired a new stake in shares of Zoetis in the third quarter worth approximately $214,000. Proficio Capital Partners LLC boosted its stake in shares of Zoetis by 3.2% in the third quarter. Proficio Capital Partners LLC now owns 2,544 shares of the company’s stock worth $443,000 after acquiring an additional 79 shares during the last quarter. Finally, RDA Financial Network boosted its stake in shares of Zoetis by 39.2% in the third quarter. RDA Financial Network now owns 2,200 shares of the company’s stock worth $383,000 after acquiring an additional 619 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Trading Up 1.6 %

NYSE:ZTS traded up $2.48 on Thursday, reaching $153.36. The company’s stock had a trading volume of 4,555,033 shares, compared to its average volume of 3,093,786. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The firm has a market cap of $70.14 billion, a price-to-earnings ratio of 30.25, a price-to-earnings-growth ratio of 2.29 and a beta of 0.85. The stock has a 50 day moving average price of $173.11 and a 200 day moving average price of $179.58.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.19 billion. During the same quarter in the prior year, the firm earned $1.15 EPS. Zoetis’s revenue for the quarter was up 8.5% compared to the same quarter last year. On average, equities analysts anticipate that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be given a $0.432 dividend. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.13%. Zoetis’s dividend payout ratio is currently 33.93%.

Analyst Ratings Changes

A number of analysts have recently issued reports on ZTS shares. The Goldman Sachs Group lifted their price target on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Stifel Nicolaus lowered their price target on Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research note on Tuesday, April 2nd. Barclays reduced their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday. Piper Sandler reiterated an “overweight” rating and set a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Finally, StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $218.00.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $173.33, for a total value of $159,983.59. Following the sale, the executive vice president now owns 15,723 shares in the company, valued at approximately $2,725,267.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have sold 2,209 shares of company stock worth $371,293. 0.12% of the stock is currently owned by company insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.